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Objective: This study was conducted to check the feasibility of using small intestine
without mucosa as a growing vascular conduit.
Method: Autologous proximal jejunum without mucosa after treatment with heparin
bonding was used as a free inferior vena cava interpositional graft between the renal
veins and bifurcation of inferior vena cava in 8 piglets. Intravenous ultrasonography
was performed at 1 to 3 months after the operation and at autopsy.
Results: One intraoperative death was related to anesthesia. At a mean follow-up of
80 days for the 7 surviving pigs, the weight had increased by 201%, from a mean
of 32 kg to a mean of 94 kg. The grafts had increased in length by 128%, from a
mean of 2.3 cm at implantation to a mean of 5.1 cm (P  .018) at explantation. In
6 animals the diameter of the graft was equal to that of the adjacent inferior vena
cava. At postmortem examination, 6 grafts were patent. The single blocked graft had
been patent 1 month after surgery. One graft had extensive septae inside, 2 had
minor septae, 2 had microscopic septae, and 2 had no septae at all. Normal
appearing adventitia, fibrous tissue, and endothelium (factor VIII-related antigen
positive) lined all the grafts. In all 7 grafts, scattered proliferating fibroblasts (MIB1
positive) were observed.
Conclusions: Small intestine without mucosa remodels and acts like a live, growing,
layered, endothelialized, nonthrombogenic (after re-endothelialization) vascular
conduit in a growing pig. This graft material could have potential as a growing
vascular conduit in children.
Vascular conduits are used to replace malfunctioning vessel seg-ment in both adults and children. Most of these conduits arehomografts, other biologic conduits, and prosthetic grafts. Chil-dren rapidly outgrow such grafts, and repeated replacements ofsuch conduits are necessary because of graft failure. Morbidityand mortality are considerably increased in this group of patients.
There is therefore a great demand for a live, growing, nonthrombogenic, endothe-
lialized vascular conduit that would resist infection and degradation, but such a
conduit is not available at present.
The small intestine was used as a vascular conduit more than 35 years ago and
even later on, but the outcome was variable in different experimental settings.1,2
Lantz and colleagues3-5 used submucosa and the deeper layers of mucosa as an
autograft, allograft, or xenograft while replacing different vessels in different
experimental designs, and they demonstrated biocompatibility and high patency
rates. Robotin-Johnson and associates6 reported their experience with small intestine
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submucosa as a template for a growing vascular conduit
while replacing superior vena cava with such a graft in
piglets.
We intended to process and use small intestine without
mucosa (SIWM) in such a way that after its implantation
into the vascular system it would adapt itself to its new
environment and work like a live, growing, endothelialized
vascular conduit. We wanted to ascertain three important
aspects of the graft. First, the graft had to be vital, growing
along with the animal. Second, the graft had to be lined with
normally functioning endothelial cells. Third, the neovas-
cular wall had to be comparable to the native inferior vena
cava (IVC) wall and well adapted to its new environment.
Material and Methods
Eight baby pigs weighing 32  4 kg were used in this study. All
animals received humane care in compliance with the Guide for
the Care and Use of Laboratory Animals prepared by the Institute
of Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996. The
experimental protocol was approved by the Governmental Veter-
inary Office, Lausanne, Switzerland.
Surgical Procedure and Graft Preparation
The animals received a clear liquid diet for 1 day before the
surgery and fasted overnight. Anesthesia was induced with ket-
amine (10 mg/kg), atropine (0.02 mg/kg), and a halothane and
oxygen mixture and was maintained with halothane and oxygen.
Harvest of small intestine. Through a midline abdomi-
nal incision, a 10-cm long piece of proximal jejunum with-
out pedicle was harvested. The continuity of the bowel was
restored in two layers with 4-0 absorbable and 4-0 nonab-
sorbable sutures.
Preparation of the SIWM graft. The graft was rinsed
thoroughly with isotonic saline solution in the beginning.
before and after processing with different solutions. The
free graft was everted, and the mucosa was gently abraded
with a cotton swab on back of a knife handle. The graft was
then again inverted, and its lumen was exposed to 1%
protamine sulfate, 0.5% glutaraldehyde, and 1% heparin
solutions for 5 minutes each in that order. This is our
modification of the technique originally described by
Miyata and coworkers7 for rendering the graft antithrombo-
genic. In this method the heparin becomes bound ionically
to protamine, which in turn combines covalently with the
collagen by the action of glutaraldehyde.7 Heparin is then
slowly released locally while endothelialization is taking
place.7
Replacement of inferior vena cava. The infrarenal IVC
was mobilized, 100 IU/kg of heparin was given intrave-
nously, vascular clamps were applied, and the middle por-
tion of infrarenal IVC between renal veins and IVC bifur-
cation was replaced with 2 cm of the SIWM graft. The graft
was plicated in 7 animals and trimmed in 1 animal to match
the size of the IVC before implantation (Figure 1). In 6
animals 6-0 Prolene sutures (Ethicon, Inc, Somerville, NJ)
were used for the anastomosis, whereas in the last 2 animals
absorbable 6.0 monofilament sutures were used. After re-
lease of the vascular clamps, the length of the graft and its
diameter at the middle of the graft were measured, the graft
and the IVC were reperitonealized, and, after hemostasis
was ensured, the abdomen was closed in layers without
drainage. Perioperative antibiotics and low-molecular
weight heparin (15,000 IU subcutaneously once a day) were
given for 5 days.
Diagnostic and Pathologic Examination
Intravascular ultrasonography (IVUS) was performed in 5 animals
1 to 3 months after implantation and in all animals when they were
Figure 1. Plicated SIWM graft at implantation.
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killed. IVUS was performed with the animals under general anes-
thesia, and the animals were given 100 IU/kg of heparin intrave-
nously just before the procedure.
After IVUS studies and before explantation, the abdomen was
opened through the midline incision and the infrarenal IVC and the
grafts were dissected free. The length of the graft and its diameter
at the center and at the site of anastomoses of the IVC and the graft
were measured. The animals were then killed with sodium pento-
thal (120 mg/kg) and potassium chloride (40 mEq) administered
intravenously. The grafts and IVC were laid open, photographs
were taken, and the specimens were fixed in 10% formalin. After
fixation of the specimens, samples were taken from four quadrants
from the middle of the graft, proximal, and distal anastomotic
junctions for histopathologic and immunohistochemical examina-
tion with hematoxylin and eosin, van Gieson-elastin stain, factor
VIII (DAKOPATTS anti-human von Willbrand factor; DAKO
A/S, Glostrup, Denmark) and MIB1 (monoclonal antibody Ki-67
antigen; Immunotech Ltd, Marseille, France) monoclonal antibod-
ies. Factor VIII and MIB1 monoclonal antibodies were used to
check the endothelial differentiation and the mural proliferative
fibroblasts, respectively, in the wall of the neograft.
Each animal acted as its own control as we took the measure-
ments at the time of implantation and explantation.
Data Analysis
Weight and length at implantation and explantation were com-
pared with the nonparametric signed-rank test for paired data. The
analyses were performed with the Stata statistical software pack-
age (Stata Corporation, College Station, Tex).
Results
One pig died during the operation of anesthesia complica-
tions. The 7 surviving pigs (Table 1) were followed up for
a mean period of 80  39 days. Their weight increased by
201%, from a mean of 32  4 kg at implantation to a mean
of 94 27 kg at explantation. The grafts increased in length
by 128%, a mean increase of 2.857  0.9 cm (P  .018)
from a mean length of 2.3  0.3 cm at implantation to a
mean length of 5.1  0.9 cm at explantation. In 6 animals
the diameter of the graft was equal to that of the adjacent
IVC. The diameter of the single blocked graft was smaller
than that of the adjoining IVC.
In 5 animals that had IVUS performed, the grafts were
patent at 1 to 3 months after implantation. At explantation,
IVUS studies showed that 6 grafts were patent but 1 was
blocked. This occluded graft had been patent during a
previous IVUS examination at 1 month after implantation
but had septae in the lumen. Of the 6 patent grafts, 2 had
macroscopic minor septae inside the graft, 2 had micro-
scopic septae, and 2 had no septae at all (Figure 2).
Pathologic Examination
After preparation and before implantation, the SIWM grafts
appeared macroscopically as thin-walled, pinkish, translu-
cent tubes when filled with isotonic saline solution. Micro-
scopically (Figures 3 and 4), the graft consisted of (from
inside out) stratum compactum, muscularis mucosae, and
lamina muscularis externa consisting of inner circular and
outer longitudinal smooth muscle layers, subserosa, and a
continuous layer of mesothelium that formed the peritoneal
serosal surface.
Control IVC tissue showed the characteristics of normal
large veins, including an intact endothelium supported by
organized lamina, fibromuscular tissue, and elastic fibers.
The tunica media of the IVC is made up of organized arrays
of smooth muscle cells. The vasa vasorum are usually
inconspicuous.
At autopsy, few adhesions were found between the loops
of bowel. The grafts and the IVC were covered with peri-
toneum and could be easily dissected out from the surround-
ing structures in 6 animals. In 1 animal which was killed 15
days after implantation of the graft, a small organizing
hematoma was found between the graft and the peritoneum.
The graft was patent in this animal. The grafts were adher-
ent to the aorta but could be dissected out. The wall of the
explanted grafts (Figure 5) was slightly thinner than that of
the IVC in the middle and slightly thicker near the anasto-
moses and the plicated area. The luminal surface in all the
grafts appeared smooth and shiny (Figure 6), although some
of the grafts contained septae. The suture lines were smooth
and flat where absorbable sutures were used and appeared as
slightly raised ridges in grafts where nonabsorbable sutures
TABLE 1. Weight, length, follow-up, and other variables at implantation and explantation
Variable N Mean  SD Minimum Maximum
Follow-up (d) 7 80.6 39.3 15.0 148.0
Weight at implantation (kg) 7 32.3 4.4 26.0 37.0
Weight at explantation (kg) 7 94.3 27.1 50.0 128.0
Increase in weight (kg) 7 62.0 29.2 13.0 101.0
Increase in weight (%) 7 201.2 107.4 35.1 374.1
Length at implantation (cm) 7 2.286 0.3 2.0 2.5
Length at explantation (cm) 7 5.143 0.9 3.5 6.0
Increase in length (cm) 7 2.857 0.9 1.0 3.5
Increase in length (%) 7 127.9 44.7 40.0 175.0
Diameter equal to IVC 7 0.9 0.4 0.0 1.0
Tucker et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 6 1167
CH
D
were used. The microscopic examination of the explanted
neografts revealed cellular intimal thickening, presence of
mononuclear inflammatory cells and giant cells near the
anastomoses and the plicated areas in the fibrocollagenous
subendothelial (tunica media) layer, no inflammatory re-
sponse in the adventitia, and a confluent flattened mono-
layer of cells (factor VIII-related antigen positive) lining
100% of the luminal surface of the graft. A rich capillary
network and intramural vessels were present across the
whole thickness of the graft. With van Gieson-elastin stain,
(Figure 7), the elastic fibers could be easily seen in the IVC,
whereas none of the grafts showed any evidence of elastic
fibers. Smooth muscle of intestinal origin could be identi-
fied only in 1 graft near the site of anastomosis, and it was
associated with calcification and granuloma formation,
probably indicative of degradation and absorption of degen-
erating muscle.
One occluded graft had macroscopic septae inside the
lumen, 2 had minor septae, and 2 had microscopic septae,
whereas 2 grafts had no septae at all. Macroscopically, the
septae were made up of a fine network of fibrous strands of
varied length, number, and thickness, all running in differ-
ent directions, and some of them had a thin translucent
membrane between different strands like a partition inside
the lumen of the graft (Figure 2, A). Microscopic examina-
tion (Figure 2, B) of the septae revealed fibrocollagenous
Figure 2. A, Photograph showing septae (S) near superior anastomosis of opened up graft and IVC. B, Photomi-
crograph of graft (GR) with attached septa (S) showing similar histologic appearance.
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tissue covered with a confluent monolayer of cells staining
positively for factor VIII-related antigen (Figure 8). The
microscopic appearances of the septae and the wall of the
graft were identical except for the adventitia. In all 7 grafts,
scattered proliferating fibroblasts (Figure 9) showed posi-
tive reaction to MIB1 antigen, indicative of active prolifer-
ation. Eight MIB1-positive fibroblasts per high-power field
(HPF, 400), could be seen in the animal killed at 15 days
after implantation of the graft. Only 1 MIB1-positive fibro-
blast per HPF could be seen in the animals killed at 71, 76,
77, 79, and 148 days after implantation (n  5). The animal
with obliterated graft, which was killed at 98 days after
implantation, showed 5 MIB1-positive fibroblasts per HPF.
Cells lining the luminal surface in all the grafts showed a
positive reaction for factor VIII-related antigen, indicative
of normal endothelial cell differentiation.
Discussion
Although the techniques of preparation, preservation, and
implantation of the vascular conduits have been refined, an
ideal vascular conduit has still not been found. For the
pediatric population the growth potential of a vascular con-
duit is important, but such a conduit is not available at
present. Pericardium is frequently used for repair of the
pulmonary arteries and sometimes also for making a vas-
cular conduit, but it is prone to calcification,8,9 shrinkage,8
and aneurysm formation.10
Matsumoto and coworkers1 in 1965 were the first to use
the small intestine as a vascular conduit in experimental
settings. Since then other surgeons2 have tried this also, but
the results have been quite variable. Lantz and colleagues3-5
developed a technique of harvesting of submucosa of the
small intestine and subsequently used it as a graft material
for veins and arteries of different sizes in different sets of
experiments. They reported that the submucosal graft acts
like a template around which endothelium and fibrocollag-
enous tissue grow, and a new vascular conduit takes shape
under a strict anticoagulation regimen. Miyata and cowork-
ers7 have described a technique of producing antithrombo-
genicity in the biologic materials and report successful use
in vascular grafts. In short, the collagen of the biologic
vascular graft is exposed to protamine sulfate, glutaralde-
hyde, and heparin, in that order. With this process, heparin
is bound ionically to protamine, which in turn is covalently
combined with the collagen. The heparin is released slowly
for several weeks, rendering the vascular graft antithrom-
bogenic.7 On the basis of work by Lantz and colleagues3-5
and Miyata and coworkers,7 Robotin-Johnson and associ-
ates6 reported their experience with the small intestinal
submucosa as a template for a growing vascular conduit in
Figure 3. Photomicrograph of graft under low power before implantation showing different layers. sm, Submucosa;
lsm, longitudinal smooth muscle; csm, circular smooth muscle; ss, subserosa; s, serosa. (Magnification 20.)
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replacing superior vena cava with such a graft in piglets.
These grafts were densely adherent to the surrounding struc-
tures, and on reviewing their results it was rather difficult to
ascertain whether the grafts had actually grown, had
stretched, or had passively distended, because the grafts
were not plicated or trimmed at the time of implantation.
We were working on the assumption that if we could
make the submucosal layer of full-thickness small intestine
(without mucosa) antithrombogenic, the external layers
might survive while endothelialization was taking place and
we might end up with a living vascular conduit. We at-
tempted to develop a live, growing, vascular conduit with
Figure 4. Photomicrograph of graft under high power before implantation showing different layers. sm, submucosa;
MM, muscularis mucosae; sc, stratum compactum. (Magnification 100.)
Figure 5. Nearly normal appearing SIWM graft with plicating sutures and IVC at explantation.
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well-adapted tunica adventitia, tunica media with smooth
muscle, and tunica intima lined with normally functioning
endothelium. Antithrombogenicity was provided to the
SIWM graft by modifying the technique of Miyata and
coworkers.7 We used a lower concentration of glutaralde-
hyde for a slightly longer duration. All reagents were ap-
plied intraluminally, with the idea of protecting the outer
layers of the graft from detrimental effects of glutaralde-
hyde.
We wanted to ascertain three important aspects of the
Figure 6. Opened up SIWM graft at explantation showing smooth, glistening endothelial surface and wide
anastomoses.
Figure 7. Photomicrograph of van Gieson-elastin stain of graft at anastomotic site showing presence of elastic
fibers (black spots with arrow) in tunica media (TM) of IVC and absence of same on graft side. ta, Tunica adventitia;
gr, graft; ti, tunica intima. (Magnification 40.)
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graft. First, the graft had to be vital and grow along with the
animal. Second, the grafts had to be lined with normally
functioning endothelial cells. Third, the neovascular wall
had to be comparable to the native IVC wall and well
adapted to its new environment. Regarding graft vitality,
these grafts had increased in length significantly (P .018),
Figure 8. Photomicrograph showing endothelial cells (ec) staining positively for factor VIII-related antigen in lining
of graft. (Magnification 200).
Figure 9. Photomicrograph of explanted graft showing proliferating fibroblasts (mf) staining positively for MIB1
antigen. (Magnification 400).
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and in 6 animals the diameter of the graft exactly matched
that of the native IVC. With MIB1 monoclonal antibody
staining, proliferating fibroblasts could be demonstrated in
the walls of all the grafts. Factors that point to the true
growth of the graft are increases in length and diameter of
the graft and increases in the size of the anastomoses with
the growth of the animal. The neografts also went into
spasm on handling, indicating living tissue under normal
tension that was not being stretched or pulled. The growth
of graft seemed to be proportional to the weight gain while
the animal was growing and not while the animal was
gaining weight after attaining maturity (Figure 10). One
animal killed at 15 days after implantation showed a 1-cm
increase in length, and the subendothelial cell layer revealed
8 proliferating fibroblasts per HPF, indicative of active
growth. On the other hand animals killed later (71, 76, 77,
79, and 148 days after implantation) had already attained
maximum growth in length and diameter, and the subendo-
thelial cell layer in these animals revealed only 1 MIB1-
positive fibroblast per HPF, indicative rather of stationary or
dormant activity. The animal with obliterated graft, killed
98 days after implantation, had doubled the length of its
graft (increase in length 2.5 cm) and showed 5 MIB1-
positive fibroblasts per HPF, probably indicative of active
cicatrization. Generalized effects of growth hormone on the
growing animal and the graft and other known growth
factors (such as fibroblast growth factors, vascular endothe-
lial growth factor, platelet-derived growth factor, and an-
giogenic peptides and nonpeptides)11 may have played sig-
nificant roles in the growth of the graft. The continued
increasing blood flow (increased blood volume with the
growth of the animal) through the IVC and the graft may
have provided the mechanical stimulus for the growth of the
graft. It is also postulated that the glutaraldehyde-tanned
inner layers of SIWM graft, after being replaced with the
fibrocollagenous tissue and inflammatory cells, got sand-
wiched between the outer surviving serosal layer and the
inner, growing endothelial cell layer. Under the influence of
previously discussed factors, the outer and the inner layers
of the graft continued to grow, compelling the subendothe-
lial fibrocollagenous layer to grow with them as a unit and
also preventing cicatrization.
Regarding graft lining, all of the grafts were lined with
normal appearing endothelial cells that showed a positive
reaction for factor VIII antigen, indicative of normal endo-
thelial cell differentiation. Pigs are well known to have
re-endothelialization of other types of bioprosthetic and
prosthetic grafts.12-14 Regarding graft structure, the IVC and
the neovascular graft in 2 animals were rather similar mac-
roscopically. Native IVC and the grafts went into spasm
when manipulated, as one would expect in a normal vessel.
Microscopically, what had been serosa was comparable to
the adventitia connective tissue. The middle layer of the
neovessel consisted of fibrocollagenous tissue in tightly and
Figure 10. Graph showing weights of animals in kilograms (circles) and lengths of grafts in millimeters (triangles)
at implantation (1) and explanation (2).
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loosely packed layers, with some capillaries and intramural
vessels. Smooth muscle was seen around intramural vessels,
but the smooth muscle of the intestinal lamina muscularis
externa could not be identified in 6 out of 7 grafts. It is
possible that glutaraldehyde had tanned the smooth muscle
layers of the small intestine during its preparation. There
were mononuclear inflammatory cells and microscopic cal-
cifications, especially near the site of anastomosis and pli-
cated areas, probably because of foreign body (suture) gran-
uloma. The innermost layer was composed of normal
appearing endothelial cells, which showed a positive reac-
tion to factor VIII-related antigen. The endothelial cells
extended from both proximal and distal anastomotic sites to
the middle of the grafts. In 1 graft major septae, in 2 grafts
minor septae, and in 2 grafts microscopic septae were
found, whereas there were no septae in 2 grafts. These
septae may have been the result of organization of mural
thrombi formed immediately after implantation of the graft.
Graft function was more or less normal despite the septae.
Septae may have been related to insufficient preparation in
some grafts. Improved graft preparation or optimal antico-
agulation could prevent this complication. There was no
obvious evidence of infection of the SIWM graft in any of
the animals. On the basis of the preceding discussion, we
could say that the SIWM graft adapted well to the new
environment.
Conclusion
Small intestine without mucosa can remodel and act like a
live, growing, layered, endothelialized, nonthrombogenic
(after re-endothelialization) vascular conduit in a growing
pig. This material may have a potential as a growing vas-
cular conduit in children. The septae were probably orga-
nized thrombi, the development of which could possibly be
controlled by optimized anticoagulation.
We acknowledge several technicians and doctors of the cardio-
thoracic and pathology laboratories who assisted in our study of
the vascular conduit, in particular Marco Burki, Antonio Mucciolo,
Gilles Godar, and Dr Bettina Marty.
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Discussion
Dr Vadiyala Reddy (San Francisco, Calif). I congratulate
Tucker and colleagues for their continuing efforts to develop a
vascular conduit that is growing in its ideal characteristics. Since
the early days of cardiothoracic surgery, the quest for ideal vas-
cular grafts, ideal heart valves, and ideal valve conduits has been
continuing. Although numerous advances have been made since
Dr DeBakey’s first hand-sewn homemade Dacron polyester fabric
graft and Dr Haufnagel’s aortic valve, the search still continues.
Today there are several choices for vascular grafts as well as
valves with excellent long-term outcomes. However, most still
require long-term antiplatelet or anticoagulant medication. In ad-
dition, these are more suitable for adult population. For a pediatric
patient, none of the existing vascular grafts or valves has the
potential to grow. This by necessity then requires reoperation as a
child outgrows the valve or the graft. Surgeons have tried to
minimize the number of reoperations by various methods, for
example by using larger grafts to account for the child’s growth or
by using in situ pericardial tubes. These strategies have resulted in
encouraging results at midterm follow-up. The need for anticoag-
ulant medication continues, however, and the potential for throm-
bosis remains. This has not been completely eliminated.
Our own experience with the use of larger polytetrafluoroeth-
ylene conduits, as well as Dr Steve Gundry’s experience with in
situ pericardial tubes at midterm follow-up, is encouraging. How-
ever, we still have to continue to anticoagulate these patients, and
the pericardium may be prone to shrinkage and calcification in the
long run.
An ideal vascular graft or valve should be biocompatible,
should resist degeneration and infection, should have good han-
dling characteristics, should be readily available in all sizes, should
grow with the patient, and should not require any long-term
medication, as outlined by Tucker and colleagues. Several inves-
tigators have worked on this, and small intestine as a vascular
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conduit was first used by Matsumoto in 1965. Since then work has
been done by several investigators, especially Robotin-Johnson
and associates of Dr Cox’s group. Currently several investigators
are exploring the newer techniques of endothelial cell seeding of
the grafts, decellularizing the autograft or xenograft tissue so that
it will form a scaffold for host tissue to invade, using biodegrad-
able polymer scaffolds with biometric flow culture systems, or,
more recently, maybe growing an entire blood vessel with genetic
engineering.
Tucker and colleagues have used the small intestine with mod-
ification, as opposed to the previous investigators. They have left
the entire small intestine and taken out only the mucosa, as
opposed to using only the intestinal submucosa itself. There was a
modification of Miyata and coworkers’s technique in using anti-
thrombogenicity. With these modifications they operated on 8
piglets, 7 of which survived. It is notable that 1 out of the 7 grafts
became blocked, which is about 15% statistically. Another concern
is that 2 of 6 grafts had macroscopic septae and another 2 had
microscopic septae. Tucker and colleagues actually attributed 1 of
the blocked grafts to this possible formation of septae. With the
short-term follow-up of 3 months, these results do not appear to me
to be encouraging. Although Tucker and colleagues demonstrated
that the conduits had grown, the graft appeared to fall short of the
ideal requirements. At pathologic examination the authors showed
fewer adhesions than with the subintestinal mucosa. These grafts
were lined by endothelial cells, as was demonstrated by previous
authors, and growth seems to have been documented.
I congratulate your group on your continuing efforts in this
regard, Dr Tucker. However, I have four questions. First, this
technique involves an abdominal operation on the patient, with the
potential for infection that has been documented previously.
Would you consider this to be a serious problem, especially if it
requires multiple operations? Second, why did you modify the
technique of antithrombogenicity as described by Miyata and
coworkers without any scientific basis for doing so? Third, the
septae are obviously a concern. Is it something to do with your
plication technique to decrease the lumen of the graft, as opposed
to doing an excision and reanastomosing this graft to appropriate
size? Fourth and most importantly, your technique does not create
a graft with any shelf life and requires an operation to retrieve the
graft. Please share your comments on this.
Dr Tucker. Thank you for the kind comments, Dr Reddy.
Regarding your first question about infection, I know that this is a
contaminated graft, a clean-contaminated graft. The jejunum is
harvested very near the duodenal-jejunal junction, and it is washed
thoroughly initially and while being prepared with different solu-
tions. It is also treated by glutaraldehyde. As you know, sometimes
the valves have been prepared with glutaraldehyde, and glutaral-
dehyde acts as a sterilizing solution also. In this study, although
clinically or macroscopically there was no evidence of infection, I
cannot say whether grafts were infected because no tests were
done. If the graft is harvested from the extreme proximal jejunum,
I do not consider it to be a serious problem.
In response to your second question, we modified the technique
of Miyata and colleagues because we wanted to get a live and
growing graft. One has to implant live tissue to get a live graft. We
a used lower concentration of glutaraldehyde intraluminally with
the idea of protecting the outer layers of the intestine from the
detrimental effects of glutaraldehyde. In all the grafts fibrous tissue
replaced the inner layers of intestine. The graft was lined by
endothelium on the inside and living serosal tissue on the outside,
allowing the graft to grow and preventing formation of stricture or
stenosis.
Regarding septae, I think that the septae have occurred because
of either inadequate antithrombogenesis or inadequate anticoagu-
lation after operation. In the future, we would refine our techniques
for the preparation, imparting antithrombogenesis to the graft and
maintaining an anticoagulation regimen after operation.
Regarding the lumen of the graft, what was your comment?
Dr Reddy. There is no shelf life to your graft. You have to
retrieve it at the time of the operation.
Dr Tucker. Yes. If you want to keep it alive, you have to
retrieve and implant it at the same time. If you leave it for a longer
time, it may not remain viable.
Dr Reddy. It is a disadvantage in terms of availability of the
grafts. One of the important things I noticed was that at 1 month
the graft that was blocked was completely patent and there were no
septae according to IVUS.
Dr Tucker. I would not say that it was completely patent.
During IVUS, there was a lot of reaction seen around the graft. The
lumen appeared smaller, so we could predict that something wrong
was going on.
Dr John Benfield (Los Angeles, Calif). The intestine needs a
blood supply to survive. You have shown slides that indicate that
the muscularis of the intestine survived without an apparent blood
supply. How did that happen?
Dr Tucker. The grafts did not show any intestinal smooth
muscles. The intestinal smooth muscles were replaced with fibrous
tissue. There were only endothelial cells, fibrous tissue, and serosa.
The layers that were fixed or treated with glutaraldehyde perished
and were replaced with fibrous tissue. Serosa survived the ill
effects of glutaraldehyde and received its nutrition from oxygen
from the blood it carried.
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